The SLC22A17 gene gives cells instructions for a receptor that binds lipocalin-2, a protein involved in iron handling and the body’s response to stress. If this gene does not work properly, cells may struggle to manage iron-related signals, which can affect cell survival and inflammation. In medicine, this gene is mainly studied for possible roles in kidney, immune, and brain function. Most variants in this gene have little effect on health.
What is a gene?
Genes are sections of DNA that give your cells instructions to make molecules or direct processes in the body. Some genes carry the directions for producing proteins, the parts of cells that do the work. Other genes mostly regulate when certain processes happen, where they take place, and how active they are. Together, genes affect how the body develops and works, and they can influence how you respond to food, stress, or medications. To look into this topic in more detail, you can learn more in the LearnHub.
Overview
SLC22A17Gene function
What if the gene works
The SLC22A17 gene helps cells respond to lipocalin-2, a protein involved in iron handling. This supports iron balance and may influence cell growth and survival, especially in tissues such as the kidney and immune system.
Risk
What if the gene does not work
Milder to more severe variants in the SLC22A17 gene can reduce how well cells bind and take up lipocalin-2, a protein that helps move iron. This may change iron handling inside cells and how those cells respond to signals.
Treatment
What does that mean for your treatment
No treatment or drug choice is currently guided specifically by pathogenic variants in the SLC22A17 gene in routine clinical guidelines. The SLC22A17 gene is under early study as a possible biomarker or drug target in some cancers and inflammatory conditions.
Gene function
What if the gene works
The SLC22A17 gene helps cells recognize and take in a protein called lipocalin-2. This process supports how cells move certain small cargo from the cell surface to the inside. Understanding how the SLC22A17 gene works in the body helps explain its part in routine cell handling of cargo linked to iron.
The SLC22A17 gene helps make a receptor, a docking protein on the cell surface, that binds lipocalin-2. This lets cells recognize this protein before bringing it inward.
After binding lipocalin-2, this receptor helps pull it into the cell in small pockets made from the cell membrane. This is part of normal cell transport and recycling.
Lipocalin-2 can carry small molecules linked to iron, and SLC22A17 helps cells take in this cargo. In this way, it supports normal cell iron handling.
What is a variant?
A genetic variant is a minor alteration in the DNA sequence of a gene. These changes are common and help account for normal differences among people, such as appearance, metabolism, or the way the body responds to environmental influences. Many variants do not have any noticeable effect and simply represent natural genetic variation. In some cases, however, a variant can change how a gene functions more substantially and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Research on how SLC22A17 gene variants affect protein function suggests some changes alter the receptor’s shape, stability, or delivery to the cell surface. This can weaken binding to lipocalin-2 and reduce receptor uptake inside the cell. Milder variants may leave partial activity, while more severe variants can truncate the protein or sharply lower its expression, leading to little or no receptor function.
How variants are linked to conditions
The SLC22A17 gene does not yet have a broadly confirmed link to a specific health condition, although research on SLC22A17 gene variants linked to conditions is still evolving. If you have a confirmed change in the SLC22A17 gene, your doctor or genetic counselor can explain what that result means in the context of your own health and family history.
A variant is not necessarily a diagnosis
Genetic changes are a routine part of human biology and are widely seen in the general population. Most variants do not have a direct effect on health and instead represent natural human diversity. For many genes, carrying a variant associated with a condition suggests a possible link rather than a definite diagnosis, especially when multiple genes and environmental factors also play a role. In some situations, though, a single well understood variant in a particular gene can be enough to confirm a diagnosis.
Are there things that can increase or change my risk?
There is not yet broadly confirmed evidence that specific lifestyle, environmental, or inherited factors clearly increase or reduce health risk related to SLC22A17. If this gene appears on a test report, a doctor or genetic counselor can help explain what it may mean in the context of your personal and family history.
Inheritance of SLC22A17 variants
Right now, the inheritance of SLC22A17 gene variants is not tied to one broadly confirmed Mendelian pattern for a specific human condition. As research stands, there is not a single well-established disease inheritance model, such as autosomal dominant or autosomal recessive, that clinicians routinely use for the SLC22A17 gene. The SLC22A17 gene is located on chromosome 14, which is an autosome, so each person inherits one copy from each parent. That means any SLC22A17 variant, if present, can be passed through either side of the family.
What does my SLC22A17 result mean for my family?
There is not yet a broadly confirmed inheritance pattern tied to a specific health condition for the SLC22A17 gene, and this picture may become clearer as research grows. If you have a specific SLC22A17 result, its meaning for parents, children, brothers, sisters, or other relatives depends on the exact change that was found and why testing was done.
Genetic information
Genetic testing
How you find out about variants
To find out whether you carry a variant in the SLC22A17 gene, a lab can do genetic testing for SLC22A17 variants using a blood or saliva sample. The test reads the gene's DNA sequence and compares it with the usual reference sequence to identify differences.
When should I consider getting a genetic test?
There is not yet a broadly established SLC22A17-specific reason for genetic testing in routine care. Testing choices are usually based on your personal health and family history, with guidance from a doctor or genetic counselor.
A genetic result is only one part of your health story
A genetic test result can provide useful insight, but how much it explains depends on the condition and on the kind of variant involved. How your body works over time is also shaped by many factors, including lifestyle, environment, age, and medical history. For some conditions, especially those influenced by many genes, genetic information offers context rather than certainty and is most helpful when considered alongside other parts of care. In other situations, a genetic result may give a clear answer. In areas like medication response, genetic results can also help put individual experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. One person may break down a drug more slowly or more quickly than another, which can change how well it works or how strongly side effects are felt. These differences are common and are one reason the same treatment can have different results in different people.
What is Pharmacogenetics?
Pharmacogenetics examines how differences in genes can affect a person’s response to medications. It studies the relationship between genes and drugs to better explain why the same treatment may work differently from one person to another. For many medicines, genes can influence how strongly a drug works or how the body processes it. This information can help support treatment decisions that are better informed and more individualized. To explore this topic further, you can learn more in the LearnHub.
Drugs influenced by the SLC22A17 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in predicting how medicines work, so questions about side effects, treatment changes, or other health concerns are best discussed with your doctor.
History
The SLC22A17 gene entered the research literature in the early 2000s, when scientists studying transport proteins identified it as a member of the SLC22 family. Initially understood only through visible traits, later recognized as tied to a specific gene, it was first described under different names, including BOCT and 24p3R, before SLC22A17 became the standard name. Soon after its discovery, researchers linked it to studies on lipocalin 2, which brought broader interest from cancer, kidney, and iron biology research groups. From these first observations, research expanded steadily. Over time, descriptions became more precise as scientists clarified where the gene is active and how it fits within this transporter family. Its history is mainly one of laboratory discovery rather than public attention.